OXB, a quality and innovation-led cell and gene therapy CDMO, has launched a new corporate brand.   Oxford Biomedica is rebranding as OXB, unveiling a more modern and recognizable visual identity that reinforces its transformation into a global pure-play cell and gene therapy CDMO.   The new identity reflects OXB’s unique combination of technical excellence, innovation and unwavering commitment to deliver consistent high quality at every stage of viral vector development and manufacturing. ...